1. Home
  2. REZI vs DYN Comparison

REZI vs DYN Comparison

Compare REZI & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Resideo Technologies Inc.

REZI

Resideo Technologies Inc.

N/A

Current Price

$20.59

Market Cap

2.7B

Sector

Industrials

ML Signal

N/A

DYN

Dyne Therapeutics Inc.

N/A

Current Price

$15.53

Market Cap

2.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
REZI
DYN
Founded
2018
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Wholesale Distributors
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.8B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
REZI
DYN
Price
$20.59
$15.53
Analyst Decision
Buy
Strong Buy
Analyst Count
6
17
Target Price
$30.67
★ $34.33
AVG Volume (30 Days)
1.6M
★ 2.2M
Earning Date
11-10-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.77
N/A
Revenue
★ $7,472,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$27.51
★ N/A
Revenue Growth
★ 10.52
N/A
52 Week Low
$15.90
$14.00
52 Week High
$42.95
$27.31

Technical Indicators

Market Signals
Indicator
REZI
DYN
Relative Strength Index (RSI) 52.84 38.49
Support Level $15.90 $14.43
Resistance Level $23.75 $19.48
Average True Range (ATR) 1.25 0.96
MACD 0.06 -0.21
Stochastic Oscillator 29.40 0.56

Price Performance

Historical Comparison
REZI
DYN

About REZI Resideo Technologies Inc.

Resideo Technologies Inc manufactures, develops, and distributes sensing and control products and solutions for residential and commercial markets. Its product portfolio includes heating, ventilation, and air conditioning (HVAC) controls, smoke and carbon monoxide detection products, fire suppression products, and security products. Its products and solutions are used in residential and commercial buildings across various countries.

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Share on Social Networks: